Journal
FRONTIERS IN ONCOLOGY
Volume 4, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2014.00349
Keywords
myeloid-derived suppressor cells; immune system; hematological malignancies; multiple myeloma; leukemia; lymphoma; stem cell transplantations
Categories
Funding
- European Commission's Seventh Framework Programme (EU FP7) OVER-MyR and International Myeloma Foundation (IMF)
Ask authors/readers for more resources
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature myeloid cells that accumulate during pathological conditions such as cancer and are associated with a poor clinical outcome. MDSC expansion hampers the host anti-tumor immune response by inhibition of T cell proliferation, cytokine secretion, and recruitment of regulatory T cells. In addition, MDSC exert non-immunological functions including the promotion of angiogenesis, tumor invasion, and metastasis. Recent years, MDSC are considered as a potential target in solid tumors and hematological malignancies to enhance the effects of currently used immune modulating agents. This review focuses on the characteristics, distribution, functions, cell cell interactions, and targeting of MDSC in hematological malignancies including multiple myeloma, lymphoma, and leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available